CIMG Inc.

Executive snapshot

Corporate status: Nevada corporation, Nasdaq-listed under ticker IMG (formerly NUZE); name and ticker changed in October 2024.
Core business: Sells Maca-based health products, traditional medicine-and-food wellness items, and computing power (AI-enabled) hardware and related services across Asia, with growing emphasis on digital marketing, distribution, and AI-driven sales.
Total revenue (FY ended 9/30/2025): $10,298,669.
Revenue mix (FY 2025):
- Maca Series: $144,726 (1.41%).
- Homology of Medicine and Food Series: $6,349,252 (61.71%) — exosome eye drops were the largest contributor within this series.
- Computing Power Product Series: $3,804,691 (36.94%).
Profitability: Net loss of approximately $4.89 million for the year ended 9/30/2025 (compared with a net loss of approximately $8.97 million in 2024). Accumulated deficit about $87.23 million as of 9/30/2025.
Customer concentration: Two customers accounted for roughly 96% of revenue (Customer A ~60%, Customer B ~36%).
Employees and footprint: 13 full-time employees as of 9/30/2025 (3 in Hong Kong; 10 in mainland China).
Global structure: 13 subsidiaries across the U.S., Hong Kong, and the PRC, including a mix of wholly owned and controlled entities.

Product examples: Maca Peptide Coffee, Maca-Noni, Maca Purified Powder, Maca Wine.
Market & distribution: Primary market is Asia; the company holds exclusive distribution and sales rights for the Kangduoyuan Maca brand in Asia for three years. Distribution through wholesale channels (grocery, convenience, vending) and expanding online retail.
Sourcing: Maca raw materials primarily from farms in Yunnan, China, with emphasis on sustainable and fair-trade practices.
Growth focus: Expand retail operations and use digital technologies to enhance marketing and diversify sales channels.

Brands and products: Includes Huomao-branded products and exosome eye drops among other health items.
Key product: Exosome eye drops (derived from exosome cells; no hormones or antibiotics).
Revenue: Represented 61.71% of total 2025 revenue; exosome eye drops made up about 60.10% of Homology revenue (approximately $3.8 million).
Channels: Primarily wholesale distribution, with plans to expand retail and digital omnichannel strategies.

Products: GPUs with embedded AI data-processing modules, customized templates, and industry-focused data-learning capabilities.
Customers: Enterprise clients integrating devices into servers and infrastructure (examples include China Merchants Bank).
Revenue: $3,804,691 in FY 2025 (36.94% of total).
Offer: Industry-specific data processing templates and marketing/data services bundled with hardware.
Roadmap: Gradual development of offerings for individual consumers in addition to enterprise sales.

Emphasis on data-driven digital marketing for Maca and Homology products.
Active expansion of online channels (TikTok, Alibaba.com, Tencent, JD.com with AI-enhanced capabilities) and omnichannel distribution.

Trademarks and domains: Six registered trademarks and four registered domain names, including PRC registrations and multiple brand assets.
Domains: Several PRC-registered domain names (examples include coco mango, ccmg) to support branding and online presence.
Product compliance: Focus on high-quality sourcing, sustainability, and compliance with food safety and labeling regulations, including China’s Food Safety Law. Chaoyang District Food Business License obtained August 23, 2024.

Subsidiaries and notable entities:
- Wewin (Florida, USA) — wholly owned.
- DZR Tech (Hong Kong) — wholly owned; parent to Braincon HK.
- Braincon Limited and Braincon HK.
- PRC subsidiaries: Beijing Xinmiao, Beijing Zhongyan, Henan Zhongyan, Nuanyou, Beijing Shangyue, Beijing Xilin, Shanghai Huomao, Zhimeng, Zhutai (Zhutai 90% owned via Shanghai Huomao).
- Singapore CIMG — wholly owned.
Offices and operations: Operational offices in Florida (Delray Beach/Boca Raton), Hong Kong, and Beijing; lease arrangements in place for 2024–2026.
PRC regulatory context: All Maca Series products approved for sale in China and covered by a Food Business License. PRC acquisitions and cross-border structuring involve regulatory review (M&A rules, CSRC considerations, SAFE filings). The company has distribution agreements and partnerships, including exclusive omni-channel sales with Beijing Zhongyan and Yimei for Kangduoyuan Maca products (July 10, 2024 to July 1, 2027).
Currency and cross-border factors: PRC foreign exchange controls (SAFE) affect cross-border fund flows; RMB fluctuations have related implications.

Revenue by segment (FY 2025):
- Maca Series: $144,726 (1.41%)
- Homology of Medicine and Food Series: $6,349,252 (61.71%)
- Computing Power Product Series: $3,804,691 (36.94%)
Net loss: ~$4,890,000 for year ended 9/30/2025; ~$8,970,000 for year ended 9/30/2024.
Accumulated deficit: Approximately $87.23 million as of 9/30/2025.
Customer concentration: Two customers combined provided about 96% of FY2025 revenue.
Employees: 13 total (3 in Hong Kong; 10 in mainland China).
Public listing: Nasdaq-listed, with a history of compliance matters and subsequent remediation; ongoing reporting requirements.

Since July 2024: Shift toward digital marketing, distribution, and sales expansion; expanded Maca distribution network in Asia and secured exclusive Kangduoyuan Maca rights for Asia.
Partnerships and agreements: Cooperation with Beijing Zhongyan and Yimei for omni-channel exclusive sales of Kangduoyuan-branded products (term July 10, 2024 to July 1, 2027).
2025 activity: Acquisitions and expansions included Beijing Xilin, Shanghai Huomao, Shenzhen Zhimeng; Braincon Limited and subsidiaries were acquired by DZR Tech; new subsidiary Nuanyou established.
Revenue focus for 2025: Homology of Medicine and Food Series is the primary revenue line, driven by exosome eye drops; Computing Power Product Series is a growing revenue contributor.

All Maca Series products are treated as pre-packaged foods in China and supported by a Food Business License (Chaoyang District, Beijing, 2024). The company makes no medical claims and positions products for health and wellness.